GLP-1 for Teens: Is Wegovy Safe at 12?
STEP TEENS Trial Data, Growth Considerations & Parent Guide (2026)
Wegovy (semaglutide) became the first GLP-1 medication FDA-approved for adolescents aged 12 and up after the STEP TEENS trial. This guide covers the clinical evidence, BMI eligibility thresholds, potential impact on growth, and the key questions parents should ask their pediatrician.
Wegovy Ages 12+, STEP TEENS Trial & Adolescent Obesity Guidance (2026)
Semaglutide (Wegovy 2.4 mg) received FDA approval in December 2022 for chronic weight management in adolescents aged 12 and older with obesity (BMI ≥95th percentile) or overweight with weight-related complications. The STEP TEENS trial demonstrated 16.1% mean BMI reduction with semaglutide vs 0.6% with placebo over 68 weeks — a historic result for pediatric obesity treatment. GLP-1 therapy in adolescents raises important considerations including growth and development monitoring, bone density, nutrition during active growth, and the psychological dimensions of obesity treatment in young patients.
Why Track This Protocol with Shotlee
Clinical Evidence
GLP-1 for Teens protocols are supported by clinical research — Shotlee helps you track your own data against published benchmarks.
Protocol Tracking
Log each dose with exact timing and amount. Consistent records help you and your provider optimize your protocol.
Outcome Monitoring
Track your key metrics before and during treatment. Objective data leads to better decisions than memory alone.
Side Effect Log
Record reactions immediately after each dose. Pattern detection prevents minor issues from becoming serious problems.
Progress Trends
Shotlee charts your data over weeks and months — see long-term trends that individual data points can hide.
Data-Driven Dosing
Your logged data tells you what works. Use Shotlee charts to make evidence-based adjustments to dose and timing.
Guide FAQs
GLP-1 medications for teenagers — Wegovy (semaglutide) FDA-approved ages 12+. STEP TEENS trial data, BMI thresholds, growth considerations.
Yes. Shotlee tracks GLP-1 and peptide doses, side effects, weight, and lab results — free to use.
PubMed, ClinicalTrials.gov, and the FDA website are the most reliable sources for current Glp1 For Teens research and regulatory updates. Peer-reviewed journals including the New England Journal of Medicine, The Lancet, and JAMA publish the most impactful clinical trial results. This guide is updated regularly to reflect the latest available evidence. Use Shotlee to track your personal protocol outcomes alongside the published research.
Before starting Glp1 For Teens, establish baseline measurements including body weight, waist circumference, blood pressure, and relevant lab work with your healthcare provider. Download Shotlee and begin logging your baseline metrics at least one week before starting treatment. This pre-treatment data provides the comparison point needed to objectively evaluate your treatment response over time. Additionally, discuss potential side effects and management strategies with your prescriber so you are prepared for the initial adaptation phase.
Evidence-based lifestyle modifications that complement Glp1 For Teens protocols include: maintaining adequate protein intake (1.2-1.6g per kg body weight per day) to preserve lean mass, performing resistance training two to three times per week, staying well hydrated with at least eight glasses of water daily, prioritizing seven to nine hours of quality sleep, managing stress through regular physical activity or mindfulness practices, and eating smaller more frequent meals during dose titration phases. Track these lifestyle factors alongside your Glp1 For Teens data in Shotlee to identify which combinations drive your best results.
Track Your GLP-1 Protocol in Shotlee
Free dose logging, side effect tracking, and health metric monitoring for your complete protocol.